Merav Bar

机构：Bristol-Myers Squibb (Germany), Medical University of Silesia, Fred Hutch Cancer Center, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland) · ORCID：0009-0007-9370-9201

发表论文 140 篇 · 总被引 4795 次 · h-index 29

代表论文

• Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study (2026 · The Lancet · 被引 8)
• New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma (2025 · Blood Advances · 被引 5)
• AI for evidence-based treatment recommendation in oncology: a blinded evaluation of large language models and agentic workflows (2025 · Frontiers in Artificial Intelligence · 被引 3)
• Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL (2025 · Blood · 被引 2)
• Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study (2026 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 1)
• Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study (2025 · Blood · 被引 1)